ARIPIPRAZOL STADA 300mg powder+solvent for suspension injection with prolonged release medication leaflet

N05AX12 aripiprazole • Nervous system | Antipsychotics | Other antipsychotics

Aripiprazole is an atypical antipsychotic used in the treatment of schizophrenia, bipolar disorder, and, in some cases, treatment-resistant major depression. It acts as a partial agonist of dopamine D2 and serotonin 5-HT1A receptors, as well as an antagonist of 5-HT2A receptors, helping to balance neurotransmitters in the brain.

Aripiprazole is available in tablet form, oral solutions, and long-acting injectable formulations. It is commonly used to reduce psychotic symptoms such as hallucinations and delusions and to stabilize mood in affective disorders.

Common side effects include nausea, dizziness, insomnia, and weight gain. In rare cases, severe adverse reactions such as neuroleptic malignant syndrome or tardive dyskinesia may occur.

Aripiprazole is an essential medication for managing psychiatric disorders, helping to improve patients' quality of life by reducing symptoms and preventing relapses.

General data about ARIPIPRAZOL STADA 300mg

Substance: aripiprazole

Date of last drug list: 01-04-2026

Commercial code: W71757001

Concentration: 300mg

Pharmaceutical form: powder+solvent for suspension injection with prolonged release

Quantity: 1

Product type: generic

Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

Manufacturer: STADA ARZNEIMITTEL AG - GERMANIA

Holder: STADA ARZNEIMITTEL AG - GERMANIA

Number: 16462/2026/01

Shelf life: 30 months-after packing for marketing;after reconstituting the solution- it is used immediately

Concentrations available for aripiprazole

10mg, 15mg, 1mg/ml, 20mg, 300mg, 30mg, 400mg, 5mg, 7.5mg/ml, 960mg